### Epidemic

**Prevalence of Hepatitis B**

<table>
<thead>
<tr>
<th></th>
<th>General Population</th>
<th>Blood Donors</th>
<th>Antenatal Clients</th>
<th>MSM</th>
<th>PWID</th>
<th>CSW</th>
<th>PLHIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute HBV</td>
<td>34%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver cancer HBV</td>
<td>61%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cirrhosis HBV</td>
<td>5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Prevalence of Hepatitis C**

<table>
<thead>
<tr>
<th></th>
<th>General Population</th>
<th>Blood Donors</th>
<th>Antenatal Clients</th>
<th>MSM</th>
<th>PWID</th>
<th>CSW</th>
<th>PLHIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute HCV</td>
<td>37%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver cancer HCV</td>
<td>62%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cirrhosis HCV</td>
<td>5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: *Blue – representative sample; **Red – non-representative sample; MSM – men who have sex with men and PWID – people who inject drugs.

### Policies

**Hepatitis B vaccine**
- Birth dose of Hep B vaccine - YES
- Hep B immunization included in routine infant immunization schedule - YES
- Vaccination for HCWs - YES
- Vaccination for high risk groups (key populations) - NO
- Hepatitis testing
  - Is there official guidance for diagnosing HBV - YES
  - Is there official guidance for diagnosing HCV - YES

### Blood & Injection safety

- Donated blood screened for Hep B & Hep C - YES
- Use of RUP syringes - YES
- Needle and syringe distribution program for PWID - NO

Source: Country survey

### Access to medicines

Availability of medicines for Hep B treatment - NO
Annual cost for Hep B treatment - NA
Availability of DAAs for Hep C treatment - NO
Annual cost for Hep C treatment - NA

### Health sector response

- National Plan for viral hepatitis - Draft
- Coverage of 3-dose Hep B vaccine schedule (2014) - 98%
- Coverage of Hep B vaccine for newborns - 98%
- Needles and syringes distributed per PWID in the last one year - NA

Source: Country survey